Clinical Trial Update: Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II clinical trial evaluating pacritinib, a JAK2/IRAK1/CSF1R inhibitor, in patients with refractory chronic graft-versus-host disease after allogeneic he…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Pacritinib (pacritinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Graft vs Host Disease | Phase 1, Phase 2 | Status: RECRUITING